TumorDiagnostik & Therapie, Table of Contents TumorDiagnostik & Therapie 2011; 32(4): 227-232DOI: 10.1055/s-0031-1281627 Thieme Onkologie Aktuell© Georg Thieme Verlag KG Stuttgart · New YorkPositronen-Emissionstomographie (PET) und PET-CT für die Therapieentscheidung in der OnkologiePositron emission tomography (PET) and PET/CT for guiding therapy in oncologyA. R. Haug1 , P. Bartenstein1 1Klinik und Poliklinik für Nuklearmedizin, Ludwig-Maximilians-Universität München Recommend Article Abstract Buy Article Schlüsselwörter Positronen-Emissionstomographie - PET - Staging - Tumortherapie - Fluorodeoxyglucose Key words positron emission tomography - PET - cancer - therapy - fluorodeoxyglucose - FDG Full Text References Literatur 1 Antoch G, Saoudi N, Kuehl H et al. Accuracy of whole-body dual-modality fluorine-18 – 2-fluoro-2-deoxy-D-glucose positron emission tomography and computed tomography (FDG-PET/CT) for tumor staging in solid tumors: comparison with CT and PET. J Clin Oncol. 2004; 22 4357-4368 2 Avril N, Sassen S, Schmalfeldt B et al. Prediction of response to neoadjuvant chemotherapy by sequential F-18-fluorodeoxyglucose positron emission tomography in patients with advanced-stage ovarian cancer. J Clin Oncol. 2005; 23 7445-7453 3 Berghmans T, Dusart M, Paesmans M et al. Primary tumor standardized uptake value (SUVmax) measured on fluorodeoxyglucose positron emission tomography (FDG-PET) is of prognostic value for survival in non-small cell lung cancer (NSCLC): a systematic review and meta-analysis (MA) by the European Lung Cancer Working Party for the IASLC Lung Cancer Staging Project. J Thorac Oncol. 2008; 3 6-12 4 Brun E, Kjellen E, Tennvall J et al. FDG PET studies during treatment: prediction of therapy outcome in head and neck squamous cell carcinoma. Head Neck. 2002; 24 127-135 5 Contractor K B, Aboagye E O. Monitoring predominantly cytostatic treatment response with 18F-FDG PET. J Nucl Med. 2009; 50 Suppl 1 97S-105S 6 Couturier O, Jerusalem G, N’Guyen J M et al. Sequential positron emission tomography using [18F]fluorodeoxyglucose for monitoring response to chemotherapy in metastatic breast cancer. Clin Cancer Res. 2006; 12 6437-6443 7 Geus-Oei L F, Laarhoven van H W, Visser E P et al. Chemotherapy response evaluation with FDG-PET in patients with colorectal cancer. Ann Oncol. 2008; 19 348-352 8 Fletcher J W, Djulbegovic de B, Soares H P et al. Recommendations on the use of 18F-FDG PET in oncology. J Nucl Med. 2008; 49 480-508 9 Frilling A, Sotiropoulos G C, Radtke A et al. The impact of 68Ga-DOTATOC positron emission tomography/computed tomography on the multimodal management of patients with neuroendocrine tumors. Ann Surg. 2010; 252 850-856 10 Gregoire V, Haustermans K, Geets X et al. PET-based treatment planning in radiotherapy: a new standard?. J Nucl Med. 2007; 48 Suppl 1 68S-77S 11 Grigsby P W, Siegel B A, Dehdashti F et al. Posttherapy [18F] fluorodeoxyglucose positron emission tomography in carcinoma of the cervix: response and outcome. J Clin Oncol. 2004; 22 2167-2171 12 Groves A M, Win T, Haim S B et al. Non-[18F]FDG PET in clinical oncology. Lancet Oncol. 2007; 8 822-830 13 Gupta N, Gill H, Graeber G et al. Dynamic positron emission tomography with F-18 fluorodeoxyglucose imaging in differentiation of benign from malignant lung/mediastinal lesions. Chest. 1998; 114 1105-1111 14 Haioun C, Itti E, Rahmouni A et al. [18F]fluoro-2-deoxy-D-glucose positron emission tomography (FDG-PET) in aggressive lymphoma: an early prognostic tool for predicting patient outcome. Blood. 2005; 106 1376-1381 15 Haug A, Auernhammer C J, Wangler B et al. Intraindividual comparison of 68Ga-DOTA-TATE and 18F-DOPA PET in patients with well-differentiated metastatic neuroendocrine tumours. Eur J Nucl Med Mol Imaging. 2009; 36 765-770 16 Haug A R, Auernhammer C J, Wangler B et al. 68Ga-DOTATATE PET/CT for the early prediction of response to somatostatin receptor-mediated radionuclide therapy in patients with well-differentiated neuroendocrine tumors. J Nucl Med. 2010; 51 1349-1356 17 Haug A R, Schmidt G P, Klingenstein A et al. F-18-fluoro-2-deoxyglucose positron emission tomography/computed tomography in the follow-up of breast cancer with elevated levels of tumor markers. J Comput Assist Tomogr. 2007; 31 629-634 18 Heinrich S, Goerres G W, Schafer M et al. Positron emission tomography/computed tomography influences on the management of resectable pancreatic cancer and its cost-effectiveness. Ann Surg. 2005; 242 235-243 19 Hillner B E, Siegel B A, Liu D et al. Impact of positron emission tomography/computed tomography and positron emission tomography (PET) alone on expected management of patients with cancer: initial results from the National Oncologic PET Registry. J Clin Oncol. 2008; 26 2155-2161 20 Hutchings M, Loft A, Hansen M et al. FDG-PET after two cycles of chemotherapy predicts treatment failure and progression-free survival in Hodgkin lymphoma. Blood. 2006; 107 52-59 21 Jadvar H. Influence of trigger PSA and PSA kinetics on (11)C-choline PET/CT detection rate in patients with biochemical relapse after radical prostatectomy. J Nucl Med. 2010; 51 498-499 ; author reply 499 – 500 22 Jadvar H. Prostate Cancer: PET with 18F-FDG, 18F- or 11C-Acetate, and 18F- or 11C-Choline. J Nucl Med. 2011; 52 81-89 23 Johansen J, Buus S, Loft A et al. Prospective study of 18FDG-PET in the detection and management of patients with lymph node metastases to the neck from an unknown primary tumor. Results from the DAHANCA-13 study. Head Neck. 2008; 30 471-478 24 Juweid M E, Stroobants S, Hoekstra O S et al. Use of positron emission tomography for response assessment of lymphoma: consensus of the Imaging Subcommittee of International Harmonization Project in Lymphoma. J Clin Oncol. 2007; 25 571-578 25 Kelly R F, Tran T, Holmstrom A et al. Accuracy and cost-effectiveness of [18F]-2-fluoro-deoxy-D-glucose-positron emission tomography scan in potentially resectable non-small cell lung cancer. Chest. 2004; 125 1413-1423 26 Lee N Y, Mechalakos J G, Nehmeh S et al. Fluorine-18-labeled fluoromisonidazole positron emission and computed tomography-guided intensity-modulated radiotherapy for head and neck cancer: a feasibility study. Int J Radiat Oncol Biol Phys. 2008; 70 2-13 27 Lordick F, Ott K, Krause B J et al. PET to assess early metabolic response and to guide treatment of adenocarcinoma of the oesophagogastric junction: the MUNICON phase II trial. Lancet Oncol. 2007; 8 797-805 28 Ott K, Herrmann K, Lordick F et al. Early metabolic response evaluation by fluorine-18 fluorodeoxyglucose positron emission tomography allows in vivo testing of chemosensitivity in gastric cancer: long-term results of a prospective study. Clin Cancer Res. 2008; 14 2012-2018 29 Palmedo H, Bucerius J, Joe A et al. Integrated PET/CT in differentiated thyroid cancer: diagnostic accuracy and impact on patient management. J Nucl Med. 2006; 47 616-624 30 Park K C, Schwimmer J, Gambhir S S. Decision analysis for the cost-effective management of recurrent colorectal cancer. Ann Surg. 2002; 235 309-310 ; author reply 310 31 Pieterman R M, Putten J W, Meuzelaar J J et al. Preoperative staging of non-small-cell lung cancer with positron-emission tomography. N Engl J Med. 2000; 343 254-261 32 Popperl van G, Gotz C, Rachinger W et al. Value of O-(2-[18F]fluoroethyl)- L-tyrosine PET for the diagnosis of recurrent glioma. Eur J Nucl Med Mol Imaging. 2004; 31 1464-1470 33 Popperl G, Tatsch K, Kreth F W et al. Brain tumors. Recent Results Cancer Res. 2008; 170 33-47 34 Prasad V, Ambrosini V, Hommann M et al. Detection of unknown primary neuroendocrine tumours (CUP-NET) using (68)Ga-DOTA-NOC receptor PET/CT. Eur J Nucl Med Mol Imaging. 2010; 37 67-77 35 Ruers T J, Wiering B, Sijp J R et al. Improved selection of patients for hepatic surgery of colorectal liver metastases with (18)F-FDG PET: a randomized study. J Nucl Med. 2009; 50 1036-1041 36 Schick van der V, Franzius C, Beyna T et al. Diagnostic impact of 18F-FDG PET-CT evaluating solid pancreatic lesions versus endosonography, endoscopic retrograde cholangio-pancreatography with intraductal ultrasonography and abdominal ultrasound. Eur J Nucl Med Mol Imaging. 2008; 35 1775-1785 37 Schuetze S M, Rubin B P, Vernon C et al. Use of positron emission tomography in localized extremity soft tissue sarcoma treated with neoadjuvant chemotherapy. Cancer. 2005; 103 339-348 38 Strobel K, Heinrich S, Bhure U et al. Contrast-enhanced 18F-FDG PET/CT: 1-stop-shop imaging for assessing the resectability of pancreatic cancer. J Nucl Med. 2008; 49 1408-1413 39 Strobel K, Skalsky J, Steinert H C et al. S-100B and FDG-PET/CT in therapy response assessment of melanoma patients. Dermatology. 2007; 215 192-201 40 Schulthess G K, Steinert H C, Hany T F. Integrated PET/CT: current applications and future directions. Radiology. 2006; 238 405-422 41 Weber D C, Zilli von T, Buchegger F et al. [(18)F]Fluoroethyltyrosine-positron emission tomography-guided radiotherapy for high-grade glioma. Radiat Oncol. 2008; 3 44 42 Weber W A. Use of PET for monitoring cancer therapy and for predicting outcome. J Nucl Med. 2005; 46 983-995 43 Weber W A, Petersen V, Schmidt B et al. Positron emission tomography in non-small-cell lung cancer: prediction of response to chemotherapy by quantitative assessment of glucose use. J Clin Oncol. 2003; 21 2651-2657 Dr. Alexander R. Haug Klinik und Poliklinik für Nuklearmedizin, Klinikum Großhadern Marchioninistr. 15 81377 München
